HC Wainwright reiterated their buy rating on shares of OpGen, Inc. (NASDAQ:OPGN) in a report issued on Wednesday. The brokerage currently has a $1.00 price target on the medical research company’s stock.
Separately, Zacks Investment Research raised OpGen from a hold rating to a buy rating and set a $0.25 price target for the company in a research note on Tuesday, August 15th.
OpGen (NASDAQ:OPGN) opened at $0.27 on Wednesday. OpGen has a one year low of $0.21 and a one year high of $3.10. The company has a debt-to-equity ratio of -0.55, a current ratio of 0.29 and a quick ratio of 0.19.
TRADEMARK VIOLATION WARNING: This article was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/hc-wainwright-reiterates-buy-rating-for-opgen-inc-opgn-2/1766475.html.
A hedge fund recently bought a new stake in OpGen stock. Perkins Capital Management Inc. purchased a new position in OpGen, Inc. (NASDAQ:OPGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned 2.72% of OpGen as of its most recent filing with the Securities and Exchange Commission (SEC). 10.86% of the stock is currently owned by hedge funds and other institutional investors.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with our FREE daily email newsletter.